BioPharma Dive September 25, 2024
The Series B round for Genespire will be used to develop a group of genetic medicines led by a prospective treatment for the rare disease methylmalonic acidemia.
Genespire, an Italy-based biotechnology startup making “off-the-shelf” gene therapies treatment for rare pediatric genetic conditions, has raised €46.6 million euros, or about $52 million, in a Series B round announced Wednesday.
The capital infusion will help Genespire advance a method of delivering lentiviral gene therapies in a more convenient way. Typically, lentiviruses — viral carriers of genetic cargo — are used in a complex process in which cells are extracted from a patient, precisely modified and re-infused. Genespire says it’s created a group of novel lentiviruses designed to be injected directly into a...
Today's Sponsors
Today's Sponsor